Natural killer cell cytolytic activity is necessary for in vivo antitumor activity of the dipeptide L-glutamyl-L-tryptophan

International Journal of Cancer

Volumn 106, Issue 4, 2003, Pages 528-533

  Smith, D Lynne ^a   Cai, Jie ^a   Zhu, SuTao ^a   Wei, Wen ^a   Fukumoto, Jon ^a   Sharma, Sanjai ^a   Masood, Rizwan ^a   Gill, Parkash S ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Antineoplastic; Immune modulatory; Natural killer cells

Indexed keywords

DIPEPTIDE; GAMMA INTERFERON; GENE PRODUCT; GLUTAMIC ACID DERIVATIVE; GLUTAMYLTRYPTOPHAN; IMMUNOMODULATING AGENT; INTERLEUKIN 12; PERFORIN; PROTEIN LYST; TRYPTOPHAN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL GRANULE; CONTROLLED STUDY; CYTOLYSIS; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOMODULATION; KNOCKOUT MOUSE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL DIVISION; CYTOPLASMIC GRANULES; CYTOTOXICITY, IMMUNOLOGIC; DIPEPTIDES; FLOW CYTOMETRY; HUMANS; INTERFERON TYPE II; INTERLEUKIN-12; KILLER CELLS, NATURAL; LUNG NEOPLASMS; MELANOMA; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASMS, EXPERIMENTAL; PORE FORMING CYTOTOXIC PROTEINS; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 0041592511     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11253     Document Type: Article

References (31)

1. Delves PJ, Roitt IM. The immune system. First of two parts. N Engl J Med 2000;343:37-49.
2. Lanier LL. Natural killer cell receptors and MHC class I interactions. Curr Opin Immunol 1997;9:126-131.
3. Smyth MJ, Trapani JA. Granzymes - exogenous proteinases that induce target cell apoptosis. Immunol Today 1995;16:202-206.
4. Berke G. The binding and lysis of target cells by cytotoxic lymphocytes: molecular and cellular aspects. Annu Rev Immunol 1994;12:735-773.
5. Brutkiewicz RR, Sriram V. Natural killer T (NKT) cells and their role in antitumor immunity. Crit Rev Oncol Hematol 2002;41:287-298.
6. Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol 1999;17:189-220.
7. Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Che X, Iwashige H, Aridome K, Hokita S, Aikou T. Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer 2000;88:577-583.
8. Salgaller ML, Lodge PA. Use of cellular and cytokine adjuvants in the immunotherapy of cancer. J Surg Oncol 1998;68:122-138.
9. Morozov VG, Khavinson VK. Natural and synthetic thymic peptides as therapeutics for immune dysfunction. Int J Immunopharmacol 1997;19:501-505.
10. Anisimov VN, Khavinson VK, Morozov VG. Immunomodulatory synthetic dipeptide L-Glu-L-Trp slows down aging and inhibits spontaneous carcinogenesis in rats. Biogerontology 2000;1:55-59.
11. Bumol TF, Reisfeld RA. Unique glycoprotein-proteoglycan complex defined by monoclonal antibody on human melanoma cells. Proc Natl Acad Sci USA 1982;79:1245-1249.
12. Lunardi-Iskandar Y, Gill P, Lam VH, Zeman RA, Michaels F, Mann DL. Reitz Jr MS, Kaplan M, Berneman ZN, Carter D, Bryant JL, Gallo RC. Isolation and characterization of an immortal neoplastic cell line (KS Y-1) from AIDS-associated Kaposi's sarcoma. J Natl Cancer Inst 1995;87:974-981.
13. Siegal B, Levinton-Kriss S, Schiffer A, Sayar J, Engelberg I, Vonsover A, Ramon Y, Rubinstein E. Kaposi's sarcoma in immunosuppression. Possibly the result of a dual viral infection. Cancer 1990;65:492-498.
14. Masood R, Cai J, Tulpule A, Zheng T, Hamilton A, Sharma S, Espina BM, Smith DL, Gill PS. Interleukin 8 is an autocrine growth factor and a surrogate marker for Kaposi's sarcoma. Clin Cancer Res 2001;7:2693-2702.
15. Morozov VG, Khavinson VK. Thymus-gland preparation and method for producing same. United States Patent No. 5,070,076.
16. Barbosa MD, Nguyen QA, Tchemev VT, Ashley JA, Detter JC, Blaydes SM, Brandt SJ, Chotai D, Hodgman C, Solari RC, Lovett M, Kingsmore SF. Identification of the homologous beige and Chediak-Higashi syndrome genes. Nature 1996;382:262-265.
17. Kagi D, Ledermann B, Burki K, Seiler P, Odermatt B, Olsen KJ, Podack ER, Zinkernagel RM, Hengartner H. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 1994;369:31-37.
18. Smyth MJ, Thia KY, Cretney E, Kelly JM, Snook MB, Forbes CA, Scalzo AA. Perforin is a major contributor to NK cell control of tumor metastasis. J Immunol 1999;162:6658-6662.
19. Hanna N, Burton RC. Definitive evidence that natural killer (NK) cells inhibit experimental tumor metastases in vivo. J Immunol 1981;127:1754-1758.
20. Habu S, Fukui H, Shimamura K, Kasai M, Nagai Y, Okumura K, Tamaoki N. In vivo effects of anti-asialo GM1. I. Reduction of NK activity and enhancement of transplanted tumor growth in nude mice. J Immunol 1981;127:34-38.
21. + cells responsible for acute marrow graft rejection are present in thymus-deficient mice. J Immunol 1992;149:403-412.
22. Takeda K, Hayakawa Y, Smyth MJ, Kayagaki N, Yamaguchi N, Kakuta S, Iwakura Y, Yagita H, Okumura K. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 2001;7:94-100.
23. Introne W, Boissy RE, Gahl WA. Clinical, molecular, and cell biological aspects of Chediak-Higashi syndrome. Mol Genet Metab 1999;68:283-303.
24. Baetz K, Isaaz S, Griffiths GM. Loss of cytotoxic T lymphocyte function in Chediak-Higashi syndrome arises from a secretory defect that prevents lytic granule exocytosis. J Immunol 1995;154:6122-6131.
25. Faltynek CR, Princler GL, Ortaldo JR. Expression of IFN-alpha and IFN-gamma receptors on normal human small resting T lymphocytes and large granular lymphocytes. J Immunol 1986;136:4134-4139.
26. Kubota A, Lian RH, Lohwasser S, Salcedo M, Takei F. IFN-gamma production and cytotoxicity of IL-2-activated murine NK cells are differentially regulated by MHC class I molecules. J Immunol 1999;163:6488-6493.
27. Smyth MJ, Kelly JM, Baxter AG, Komer H, Sedgwick JD. An essential role for tumor necrosis factor in natural killer cell-mediated tumor rejection in the peritoneum. J Exp Med 1998;188:1611-1619.
28. Kobayashi M, Fitz L, Ryan M, Hewick RM, Clark SC, Chan S, Loudon R, Sherman F, Perussia B, Trinchieri G. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 1989;170:827-845.
29. Hyodo Y, Matsui K, Hayashi N, Tsutsui H, Kashiwamura S, Yamauchi H, Hiroishi K, Takeda K, Tagawa Y, Iwakura Y, Kayagaki N, Kurimoto M, et al. IL-18 up-regulates perforin-mediated NK activity without increasing perforin messenger RNA expression by binding to constitutively expressed IL-18 receptor. J Immunol 1999;162:1662-1668.
30. Hashimoto W, Osaki T, Okamura H, Robbins PD, Kurimoto M, Nagata S, Lotze MT, Tahara H. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively. J Immunol 1999;163:583-589.
31. Lauwerys BR, Garot N, Renauld JC, Houssiau FA. Cytokine production and killer activity of NK/T-NK cells derived with IL-2, IL-15, or the combination of IL-12 and IL-18. J Immunol 2000;165:1847-1853.